Director/PDMR Shareholding

Regulatory News Service

27 March 2017 at 15:00

AstraZeneca PLC (the Company) announces that, on 24 March 2017, certain Persons Discharging Managerial Responsibilities of the Company (PDMRs) were each granted awards of the Company’s ordinary shares of $0.25 each (Ordinary Shares) or of American Depositary Shares (ADSs) under the terms of the AstraZeneca Deferred Bonus Plan (AZDBP) and the AstraZeneca Performance Share Plan (AZPSP), as detailed in the table below. Two ADSs are equivalent to one Ordinary Share.


Ordinary Shares awarded under the AZDBP

ADSs awarded under the AZDBP

Ordinary Shares awarded under the AZPSP

ADSs awarded under the AZPSP

Award price per Ordinary Share / per ADS

Pascal Soriot






Marc Dunoyer






Sean Bohen






Mark Mallon






The AZDBP award represents the portion of each PDMR’s annual bonus for 2016 that they are required to defer into shares. The Ordinary Shares and ADSs awarded under the AZDBP are subject to a three-year holding period (24 March 2017 to 23 March 2020).

The AZPSP award is subject to a combination of performance measures focused on scientific, commercial and financial performance assessed over a three-year performance period (1 January 2017 to 31 December 2019). The AZPSP award will vest on the third anniversary of the date of grant, other than the awards granted to the Executive Directors, Mr Soriot and Mr Dunoyer, which will be subject to a further two-year holding period before vesting.

Details of the performance measures attached to the AZPSP award can be found in the Directors' Remuneration Report within the AstraZeneca Annual Report and Form 20-F Information 2016, which is available on the Company's website at

The Company also announces that, on 24 March 2017, Mr Bohen was granted an award of 48,753 ADSs under the terms of the AstraZeneca Restricted Share Plan (AZRSP) at an award price of $30.88 per ADS. The ADSs awarded under the AZRSP are subject to continued employment and will vest on the third anniversary of the date of grant.

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas - Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company also is selectively active in the areas of Autoimmunity, Neuroscience and Infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit and follow us on Twitter @AstraZeneca.


Media Enquiries





Esra Erkal-Paler


+44 203 749 5638

Vanessa Rhodes


+44 203 749 5736

Karen Birmingham


+44 203 749 5634

Rob Skelding


+44 203 749 5821

Jacob Lund


+46 8 553 260 20

Michele Meixell


+1 302 885 2677





Investor Relations



Thomas Kudsk Larsen


+44 203 749 5712

Craig Marks

Finance, Fixed Income, M&A

+44 7881 615 764

Henry Wheeler


+44 203 749 5797

Mitchell Chan


+1 240 477 3771

Lindsey Trickett

Cardiovascular & Metabolic Diseases

+1 240 543 7970

Nick Stone


+44 203 749 5716

Christer Gruvris

Autoimmunity, neuroscience & infection

+44 203 749 5711

US Toll-Free


+1 866 381 7277

Adrian Kemp
Company Secretary
AstraZeneca PLC


  • Regulatory